ACER THERAPEUTICS INC (ACER) Stock Price, Forecast & Analysis
NASDAQ:ACER • US00444P1084
ACER Key Statistics, Chart & Performance
The current stock price of ACER is 0.9 USD. In the past month the price increased by 20%. In the past year, price decreased by -26.83%.
ACER Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ACER. When comparing the yearly performance of all stocks, ACER turns out to be only a medium performer in the overall market: it outperformed 51.09% of all stocks.
ACER Financial Highlights
Over the last trailing twelve months ACER reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -88.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -225.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACER Forecast & Estimates
8 analysts have analysed ACER and the average price target is 1.53 USD. This implies a price increase of 70% is expected in the next year compared to the current price of 0.9.
ACER Ownership
ACER Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 981.56B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 589.194B | ||
| MRK | MERCK & CO. INC. | 22.44 | 295.956B | ||
| PFE | PFIZER INC | 9.18 | 156.186B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 121.86B | ||
| ZTS | ZOETIS INC | 18.44 | 55.368B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 25.86B | ||
| VTRS | VIATRIS INC | 6.23 | 18.186B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.317B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.222B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACER
Company Profile
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. The company is headquartered in Newton, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2006-09-01. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Company Info
ACER THERAPEUTICS INC
One Gateway Center (300 Washington St.), Suite 356
Newton MASSACHUSETTS 02458 US
CEO: Chris Schelling
Employees: 33
Phone: 18449026100.0
ACER THERAPEUTICS INC / ACER FAQ
Can you describe the business of ACER THERAPEUTICS INC?
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. The company is headquartered in Newton, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2006-09-01. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
What is the stock price of ACER THERAPEUTICS INC today?
The current stock price of ACER is 0.9 USD. The price increased by 3.41% in the last trading session.
Does ACER stock pay dividends?
ACER does not pay a dividend.
What is the ChartMill rating of ACER THERAPEUTICS INC stock?
ACER has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How is the valuation of ACER THERAPEUTICS INC (ACER) based on its PE ratio?
ACER THERAPEUTICS INC (ACER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
Can you provide the market cap for ACER THERAPEUTICS INC?
ACER THERAPEUTICS INC (ACER) has a market capitalization of 22.01M USD. This makes ACER a Nano Cap stock.